Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

Summary

This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with lung cancer.

Timeline

Start

2018-07-19

Primary completion

2026-09

Completion

2026-09

Drugs

Indications